DSE : AMBEEPHA
Ambee Pharmaceuticals PLC — Key statistics
Pharmaceutical Preparations · Bangladesh
Last price 730.7 BDT (At close: Oct 29, 2026) · Market cap 1.75B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Technical report: trend, RSI, support and resistance, charts
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.75B |
| Enterprise Value | 2.32B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | Nov 23, 2025 |
Shares
| Measure | Value |
|---|
| Current Share Class | 2.40M |
| Shares Outstanding | 2.40M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 77.25% |
| Owned by Institutions (%) | n/a |
| Float | 545,941 |
Ratios
| Measure | Value |
|---|
| PE Ratio | 317.27 |
| Forward PE | n/a |
| PS Ratio | 11.13 |
| PB Ratio | 49.60 |
| P/TBV Ratio | 49.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 419.04 |
| EV / Sales | 14.70 |
| EV / EBITDA | 261.56 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.85 |
| Quick Ratio | 0.44 |
| Debt / Equity | 18.68 |
| Debt / EBITDA | 74.58 |
| Debt / FCF | n/a |
| Interest Coverage | 119.99 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 16.36% |
| Return on Assets (ROA) | 0.34% |
| Return on Invested Capital (ROIC) | 0.50% |
| Return on Capital Employed (ROCE) | 10.41% |
| Weighted Average Cost of Capital (WACC) | 2.20% |
| Revenue Per Employee | 332,515 |
| Profits Per Employee | 11,661 |
| Employee Count | 474 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 0.36 |
Taxes
| Measure | Value |
|---|
| Income Tax | 2.10M |
| Effective Tax Rate | 27.49% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.22 |
| 52-Week Price Change | -8.75% |
| 50-Day Moving Average | 750.48 |
| 200-Day Moving Average | 759.17 |
| Relative Strength Index (RSI) | 39.27 |
| Average Volume (20 Days) | 449 |
Shortselling
| Measure | Value |
|---|
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Incomestatement
| Measure | Value |
|---|
| Revenue | 157.61M |
| Gross Profit | 72.95M |
| Operating Income | 4.06M |
| Pretax Income | 7.62M |
| Net Income | 5.53M |
| EBITDA | 8.50M |
| EBIT | 4.06M |
| Earnings Per Share (EPS) | 2.30 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 97.86M |
| Total Debt | 660.41M |
| Net Cash | -562.54M |
| Net Cash Per Share | -234.39 |
| Equity (Book Value) | 35.36M |
| Book Value Per Share | 14.73 |
| Working Capital | -110.21M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -18.41M |
| Capital Expenditures | 254 |
| Depreciation & Amortization | 4.44M |
| Net Borrowing | 36.28M |
| Free Cash Flow | -18.41M |
| FCF Per Share | -7.67 |
Margins
| Measure | Value |
|---|
| Gross Margin | 46.28% |
| Operating Margin | 2.57% |
| Pretax Margin | 4.84% |
| Profit Margin | 3.51% |
| EBITDA Margin | 5.39% |
| EBIT Margin | 2.57% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | 1.00 |
| Dividend Yield | 0.14% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 39.37% |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 0.14% |
| Earnings Yield | 0.32% |
| FCF Yield | -1.05% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | May 29, 2014 |
| Split Type | Forward |
| Split Ratio | 1.2 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.63 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |